# Open-label Trial in Parkinson's Disease (PD)

> **NCT04760769** · PHASE3 · COMPLETED · sponsor: **AbbVie** · enrollment: 992 (actual)

## Conditions studied

- Parkinson Disease

## Interventions

- **DRUG:** Tavapadon

## Key facts

- **NCT ID:** NCT04760769
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-02-24
- **Primary completion:** 2025-12-01
- **Final completion:** 2025-12-01
- **Target enrollment:** 992 (ACTUAL)
- **Last updated:** 2025-12-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04760769

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04760769, "Open-label Trial in Parkinson's Disease (PD)". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04760769. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*